Trial Profile
Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment - lessons learned
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 28 Dec 2015 New trial record